评估树突状细胞疗法和病毒疗法在高级别胶质瘤临床试验中的疗效。一项荟萃分析综述。
Assessment of efficacy of dendritic cell therapy and viral therapy in high grade glioma clinical trials. A meta-analytic review.
作者信息
Vatu Bogdan Ionel, Artene Stefan-Alexandru, Staicu Adeline-Georgiana, Turcu-Stiolica Adina, Folcuti Catalin, Dragoi Alexandra, Cioc Catalina, Baloi Stefania-Carina, Tataranu Ligia Gabriela, Silosi Cristian, Dricu Anica
机构信息
a Department of Biochemistry , University of Medicine and Pharmacy of Craiova , Craiova , Romania.
b Department of Biostatistics , University of Medicine and Pharmacy of Craiova , Craiova , Romania.
出版信息
J Immunoassay Immunochem. 2019;40(1):70-80. doi: 10.1080/15321819.2018.1551804. Epub 2018 Nov 30.
In recent years, immunotherapy has raised the interest of many studies and provided different perspectives for the therapeutic management of high grade glioma. Our meta-analysis focused on the effectiveness of dendritic cell (DC) therapy and viral therapy (VT) in clinical trials. Fourteen eligible studies have been evaluated and the results suggest the improvement of both OS (HR = 0.65) (p < 0.0001) and PFS (HR = 0.59) (p = 0.01) for patients receiving DC therapy. The data for VT showed a slight improvement in terms of OS (HR = 0.81), while PFS was similar to the control arms (HR = 1.06) (p = 0.41).
近年来，免疫疗法引起了众多研究的关注，并为高级别胶质瘤的治疗管理提供了不同的视角。我们的荟萃分析聚焦于临床试验中树突状细胞（DC）疗法和病毒疗法（VT）的有效性。已评估了14项符合条件的研究，结果表明接受DC疗法的患者总生存期（OS）（风险比[HR]=0.65）（p<0.0001）和无进展生存期（PFS）（HR=0.59）（p=0.01）均有所改善。VT的数据显示OS略有改善（HR=0.81），而PFS与对照组相似（HR=1.06）（p=0.41）。
Zotero 插件